Table 2.
Changes in estimated glomerular filtration rate (eGFR), CD4+ T cell count (CD4), and lipids at 24 and 48 weeks after starting darunavir/cobicistat
| Dual therapy | Triple therapy | P between groups | |||
|---|---|---|---|---|---|
| Mean | SD | Mean | SD | ||
| eGFR mL/min | |||||
| T0 | 94.2 | 20.3 | 96.3 | 23.6 | |
| T1 | 90.2 | 19.0 | 88.7 | 21.7 | |
| T2 | 86.7 | 17.7 | 87.7 | 18.6 | |
| T1-T0 (mean, SE) | − 4.6* | 1.8 | − 7.6* | 1.3 | 0.19 |
| T2-T0 (mean, SE) | − 7.6* | 1.9 | − 8.5* | 1.4 | 0.71 |
| CD4 cells/mm3 | |||||
| T0 | 625.2 | 381.0 | 580.6 | 342.9 | |
| T1 | 653.3 | 309.2 | 641.0 | 364.4 | |
| T2 | 712.6 | 326.0 | 664.1 | 365.0 | |
| T1-T0 (mean, SE) | 18.5 | 30.5 | 60.8* | 15.6 | 0.22 |
| T2-T0 (mean, SE) | 35.3 | 26.7 | 64.2* | 19.1 | 0.38 |
| HDL mg/dL | |||||
| T0 | 51.0 | 16.6 | 47.0 | 14.8 | |
| T1 | 50.2 | 15.6 | 47.9 | 14.8 | |
| T2 | 52.8 | 16.3 | 47.3 | 15.2 | |
| T1-T0 (mean, SE) | − 1.2 | 1.0 | 1.2 | 0.8 | 0.07 |
| T2-T0 (mean, SE) | 1.8 | 2.2 | 0.7 | 1.2 | 0.62 |
| TC mg/dL | |||||
| T0 | 200.0 | 47.6 | 187.3 | 42.5 | |
| T1 | 199.4 | 45.8 | 190.0 | 40.8 | |
| T2 | 204.5 | 45.3 | 192.5 | 46.6 | |
| T1-T0 (mean, SE) | − 1.2 | 3.6 | 3.6 | 2.3 | 0.24 |
| T2-T0 (mean, SE) | 0.1 | 5.0 | 2.4 | 3.3 | 0.69 |
| TG mg/dL | |||||
| T0 (median, IQR) | 128 | 92–169 | 124 | 88–168 | |
| T1 (median, IQR) | 133 | 97–177 | 111 | 86–167 | |
| T2 (median, IQR) | 145 | 90–183 | 120 | 86–194 | |
| T1-T0 (mean, SE) | 32.3 | 31.7 | − 5.7 | 4.4 | 0.24 |
| T2-T0 (mean, SE) | 4.3 | 8.6 | 3.3 | 6.5 | 0.92 |
| TC/HDL | |||||
| T0 | 4.20 | 1.34 | 4.27 | 1.37 | |
| T1 | 4.26 | 1.39 | 4.25 | 1.38 | |
| T2 | 4.11 | 1.21 | 4.31 | 1.29 | |
| T1-T0 (mean, SE) | 0.07 | 0.08 | − 0.05 | 0.08 | 0.31 |
| T2-T0 (mean, SE) | − 0.13 | 0.14 | − 0.05 | 0.09 | 0.62 |
SD: Standard deviation; SE: standard error; T0: baseline; T1: 24 week follow up; T2: 48 week follow up; TC: total cholesterol, TG: triglycerides; HDL: HDL cholesterol
* P for change from baseline < 0.05